Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
- PMID: 36777764
- PMCID: PMC9909475
- DOI: 10.3389/fpubh.2022.1046546
Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
Keywords: COVID-19; Ethiopia; dose; heterologous; homologous; intradermal; intramuscular; vaccine.
Conflict of interest statement
LWo is a senior advisor to the MoH in Ethiopia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.Front Immunol. 2023 Aug 1;14:1237916. doi: 10.3389/fimmu.2023.1237916. eCollection 2023. Front Immunol. 2023. PMID: 37593732 Free PMC article. Clinical Trial.
-
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4. Hum Vaccin Immunother. 2023. PMID: 37140889 Free PMC article.
-
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
-
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.Biomed Pharmacother. 2022 Mar;147:112650. doi: 10.1016/j.biopha.2022.112650. Epub 2022 Jan 19. Biomed Pharmacother. 2022. PMID: 35066301 Free PMC article. Review.
-
Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination.Front Public Health. 2023 Jan 12;10:960598. doi: 10.3389/fpubh.2022.960598. eCollection 2022. Front Public Health. 2023. PMID: 36711369 Free PMC article.
Cited by
-
Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S37-S46. doi: 10.1093/cid/ciaf130. Clin Infect Dis. 2025. PMID: 40694514 Free PMC article. Clinical Trial.
References
-
- Ethiopia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data . Available online at: https://covid19.who.int (accessed December 21, 2021).
-
- Batra K, Acheampong Je Batra R, Lopey M, Wu P, Arora S, Saluja P, et al. . Evolution of SARS-CoV-2 variants: a rapid literature scan. J Health Soc Sci. (2022) 7:141–51. 10.19204/2022/VLTN3 - DOI
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical